Auspex Pharma soars on Huntington’s disease drug trial

By |2017-04-25T18:03:50+00:00December 19th, 2014|Pharma News|

(Reuters) - Shares of Auspex Pharmaceuticals Inc soared about 60 percent on Tuesday after the drug developer said its product for treating chorea, or involuntary movement associated with Huntington's disease, met the main goal in a late-stage study. The shares jumped about to $40 in extended trading after closing at $25.09 on Nasdaq. Patients administered [...]

Read More
Comments Off on Auspex Pharma soars on Huntington’s disease drug trial

Biotech Entrepreneur Tony Coles Takes Aim At Parkinson’s And Alzheimer’s

By |2017-04-25T18:03:51+00:00December 15th, 2014|Pharma News|

Tony Coles, the chief executive who sold Onyx Pharmaceuticals to Amgen AMGN -2.45% for $10.4 billion in 2013, is starting a new company that will use yeast to try and discover new treatments for Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease.) The new startup, Yumanity, will be based in [...]

Read More
Comments Off on Biotech Entrepreneur Tony Coles Takes Aim At Parkinson’s And Alzheimer’s
Go to Top